New York City’s newest public health threat to human health and the human race is the human gene therapy of stage 1 melanomas.
The news comes a day after the nation’s largest university announced a $1.8 billion commitment to the therapy, which involves removing melanoma cells from the body to produce new blood cells.
In the coming years, scientists hope the treatment could save thousands of lives by preventing the spread of the disease, which has claimed the lives of more than 10,000 people since it was discovered in a California university student in 2011.
The disease is now the second-leading cause of death in the U.S., after heart disease.
In some parts of the country, the number of deaths from the disease has quadrupled since 2010, when more than 14,000 cases were reported.
The NIH has been developing a treatment for the disease since 2005.
It has tested nearly 40,000 patients and has seen a significant drop in deaths from stage 1.
But even though the NIH is funding a $10 million clinical trial in New York this year, the agency said it will not release details about the results of the trial until 2018.
The trial, known as Phase 2b, is being led by Dr. Thomas Geisler, the head of the New York State Department of Health.
The NIH has partnered with Dr. Eric D. Koonin, a pioneer in the field.
Koonin said that while there was a reduction in mortality in the study, there were no significant differences in the results among the patients treated with the gene therapy.
He said that the results are important to inform the next phase of the study.
Dr. Michael J. Siegel, chief medical officer for the American Academy of Dermatology, which represents the dermatology community, called the study a promising sign of progress in the battle against melanoma.
“There is still a lot to be done,” Siegel said in a statement.
“The hope is that the trial results will be presented in a more transparent manner.”
The results of phase 2b are expected to be released in 2018.
If approved, it would be the first time a gene therapy has been approved by the FDA for use in humans, although previous trials have shown promising results in mice.
But the treatment has been controversial because of concerns about the potential side effects, including a high risk of liver damage.
Sixty-nine percent of patients who have received gene therapy have died, compared with 14 percent of people who received chemotherapy.